Evidence gap analysis for a biologic treatment in severe atopic dermatitis

Our mid-sized pharma client had a new product in Phase 3 trials for severe atopic dermatitis.

Demonstrating the product’s benefits versus lower-cost topical and oral treatments, and the severe burden of disease, was critical in order to justify the target price.

The client sought advice on how well the existing trial data would meet payers’ requirements, and recommendations for additional studies and analyses that could support the product’s overall value proposition.

Challenge

Our client wanted to assess how well Phase 3 trials of a product for severe atopic dermatitis would meet payer requirements, and any improvements or additions to the evidence package which could enhance the value proposition.

How we helped

We conducted an in-depth review of the trial protocol and target product profile, alongside existing treatments and the burden of disease in atopic dermatitis.

A payer value proposition was then developed, including existing data as well as mock-up evidence from planned activities.

Feedback affiliate was sought and incorporated, via a multi-country workshop. After that, the proposition – including additional analyses to support the product’s clinical and economic benefits – was tested with payers in Europe and the US.

Detailed payer feedback helped refine the final recommendations.

Outcome

Developing and testing the payer value proposition before Phase 3b trials began meant that these could be designed to generate the most compelling evidence in support of the product’s clinical and economic benefits.

This led to strong, evidence-backed messaging for the drug and a satisfied client who was confident in the product’s positioning and price point.